News

China forces insulin price cuts resulting in pullback for global pharma players

Xinhua, a Chinese news channel, commented on the price cut on insulin which was brought on by China’s volume-based procurement (VBP) program....

Aussie pharma CSL in talks to buy Swiss firm Vifor Pharma for USD 7B

CSL, the Australian giant, is in talks to buy Vifor Pharma in a deal that is valued at $7B, or A$10B. Vifor...

Sanofi to acquire Origimm Biotechnology in a bid to expand vaccine pipeline

Sanofi will acquire Origimm Biotechnology as per an agreement signed by the two healthcare companies. The deal is expected to be finalized...

Is Biogen’s Alzheimer’s drug worth $56K? Experts say $8400 and raise questions about efficacy

Aduhelm, Biogen’s new drug for Alzheimer’s disease, which was approved by FDA contentiously last month, continues to face criticism since then.

AstraZeneca and FibroGen hit FDA committee’s safety data firewall for roxadustat

Two roxadustat partners AstraZeneca and FibroGen have received objections regarding safety concerns of their drug from the FDA after which the two companies

NRx Pharmaceuticals signs deal for clinical trials of Israel’s homegrown Covid-19 vaccine

Israel Institute for Biological Research (IIBR), an institute run by Israel’s Defense Ministry, has signed a memorandum of understanding (MoU) with the NRx Pharmaceuticals

Pharma manufacturers lawsuits against payers and benefit managers preferred drugs are on FTC’s radar

The attention of federal antitrust regulators has been drawn to a slew of lawsuits filed by pharmaceutical companies, challenging the “preferred” medicine list of payers and benefit managers.

Roche to lay off 300 to 400 employees in product development jobs

Roche’s executives, including CMO (Chief Medical Officer) Levi Garraway, claimed in a recorded video conference with staff acquired by Swiss Newspaper Blick

Latest news

Sionna Therapeutics Targets $156 Million in IPO to Advance Cystic Fibrosis Research

Sionna Therapeutics, a biotechnology firm headquartered in Waltham, Massachusetts, is preparing to raise up to $156 million through an...

AdvanCell Bags $112M in Series C Funding For Alpha Radiopharma Trial

AdvanCell has raised $112 million in a Series C fundraising round supported by Sanofi Ventures. The Australian radiopharmaceutical firm...

Atalanta Therapeutics Secures $97 Million to Advance siRNA Therapies for Neurological Disorders

Atalanta Therapeutics has raised $97 million in a successful Series B financing round, which will support the initiation of...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you

Merus Faces Setback Following Interim Report for Lung Cancer Therapy

Merus, a biopharmaceutical company, confronted a significant...

Roivant Bids Farewell to Lupus Treatment Following Phase 2 Failure

Roivant CEO Matt Gline had never been...

Moderna revenue falls as pandemic wanes

When Moderna entered into an agreement with...